All In Biotech

Drug Trial Radar · NCT00277602

Riluzole in Huntington's Disease

A Phase III Multicenter, Double-Blind, Parallel-Group, Placebo Controlled Study to Measure the Effect of Riluzole 50 mg b.i.d. Over a Period of Three Years on the Progression of Huntington's Disease

Last checked: Nov 20, 2026Latest source record: Feb 17, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 537 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

537

Actual

Start

Nov 1999

Primary completion

Jul 2004

Study completion Jul 2004

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jan 16, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 25 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary objective: * The primary objective of the study is to establish that riluzole slows down (1) the decrease in total functional capacity (TFC), (2) the increase of the motor score of the Unified Huntington's Disease Rating Scale (UHDRS) as well as (3) the increase of a combined score of these. Secondary objectives: Secondary objectives are to assess * changes in the other UHDRS subscales * the number of patients who need antichoreic treatment and the time until this treatment has to be initiated * the safety/tolerability of riluzole in Huntington patients

Conditions

  • Huntington Disease

Interventions

  • RiluzoleDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. UHDRS-motor score, TFC

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.